Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview.
Vázquez JC, Piñero A, de Castro FJ, Lluch A, Martín M, Barnadas A, Alba E, Rodríguez-Lescure Á, Rojo F, Giménez J, Solá I, Quintana MJ, Bonfill X, Urrutia G, Sánchez-Rovira P. Vázquez JC, et al. Clin Transl Oncol. 2022 Sep;24(9):1744-1754. doi: 10.1007/s12094-022-02824-9. Epub 2022 Apr 12. Clin Transl Oncol. 2022. PMID: 35414152 Review.
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Alba E, et al. J Clin Oncol. 2004 Jul 1;22(13):2587-93. doi: 10.1200/JCO.2004.08.125. J Clin Oncol. 2004. PMID: 15226326 Clinical Trial.
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Estévez LG, Sánchez-Rovira P, Dómine M, León A, Calvo I, Jaén A, Casado V, Rubio G, Díaz M, Miró C, Lobo F, Carrasco E, Casillas M, San Antonio B. Estévez LG, et al. Clin Transl Oncol. 2007 May;9(5):317-22. doi: 10.1007/s12094-007-0059-7. Clin Transl Oncol. 2007. PMID: 17525042 Clinical Trial.
Current controversies in the management of early breast cancer.
Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I. Estévez LG, et al. Clin Transl Oncol. 2007 Jun;9(6):375-84. doi: 10.1007/s12094-007-0070-z. Clin Transl Oncol. 2007. PMID: 17594952 Review.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Clin Transl Oncol. 2008 Oct;10(10):646-53. doi: 10.1007/s12094-008-0265-y. Clin Transl Oncol. 2008. PMID: 18940745 Clinical Trial.
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9. Am J Clin Oncol. 2010. PMID: 19952716 Clinical Trial.
126 results